EP3917559A1 - Therapeutic protein flow kit for a continuous purification system - Google Patents
Therapeutic protein flow kit for a continuous purification systemInfo
- Publication number
- EP3917559A1 EP3917559A1 EP20748801.6A EP20748801A EP3917559A1 EP 3917559 A1 EP3917559 A1 EP 3917559A1 EP 20748801 A EP20748801 A EP 20748801A EP 3917559 A1 EP3917559 A1 EP 3917559A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- kit
- flow
- serum
- static mixer
- flow kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 38
- 238000000746 purification Methods 0.000 title claims abstract description 35
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 34
- 210000002966 serum Anatomy 0.000 claims abstract description 62
- 238000002156 mixing Methods 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 41
- 230000003068 static effect Effects 0.000 claims description 40
- 238000004587 chromatography analysis Methods 0.000 claims description 24
- 238000012545 processing Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- 229920003023 plastic Polymers 0.000 claims description 12
- 239000004033 plastic Substances 0.000 claims description 12
- 238000005070 sampling Methods 0.000 claims description 8
- 238000010146 3D printing Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000000465 moulding Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000001746 injection moulding Methods 0.000 claims description 5
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 3
- 238000000071 blow moulding Methods 0.000 claims description 3
- 239000004917 carbon fiber Substances 0.000 claims description 3
- 238000010097 foam moulding Methods 0.000 claims description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 239000004616 structural foam Substances 0.000 claims description 3
- 238000003856 thermoforming Methods 0.000 claims description 3
- 238000011109 contamination Methods 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 31
- 239000012530 fluid Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 239000012538 diafiltration buffer Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229920005669 high impact polystyrene Polymers 0.000 description 2
- 239000004797 high-impact polystyrene Substances 0.000 description 2
- -1 polyethylene terephthalate Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011100 viral filtration Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101000972349 Phytolacca americana Lectin-A Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011035 continuous diafiltration Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/45—Mixing liquids with liquids; Emulsifying using flow mixing
- B01F23/451—Mixing liquids with liquids; Emulsifying using flow mixing by injecting one liquid into another
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
- B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
- B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
Definitions
- the present invention relates to a therapeutic protein flow kit for a continuous purification system.
- therapeutic fluid serums containing antibodies, interferon or other therapeutic proteins are essential for the treatment of myriad autoimmune and inflammatory diseases.
- the disorders associated with such treatment are many and often well-known, including crohn’s disease, colitis, lupus, multiple sclerosis, psoriasis and others.
- the mechanisms by which therapeutic proteins treat the manifestations of such disorders are varied and, to ensure an effective response in specifically targeted tissue, it is essential that a given serum be properly formulated to contain the appropriate target protein(s) in the appropriate concentration(s), without the presence of extraneous proteins or other types of contamination.
- a common monoclonal antibody purification process will consist of a Protein A affinity chromatography step, a low pH viral inactivation step, an anion exchange step (membrane or chromatography), a virus filtration step, a cation exchange chromatography step, and a diafiltration and concentration step. These steps typically provide orthogonal means of removing impurities that include DNA, viruses, host cell proteins, product impurities, etc.
- a traditional batch process would hold a 200L batch in a 200L tank between each of the described steps, in comparison to a 200 mL to 2 L vessel used in a continuous process.
- Reduced flow rates of the process allow for reduced piping or tubing sizes from 1/2” to 1/8”, for the same size batch. This reduction in equipment size provides new opportunities for flow kits that directly meet the needs of a continuous process.
- Flow kits are known devices for the mixing of components of therapeutic serums, including those containing antibodies.
- a flow kit for production of a therapeutic protein serum will contain one or more vessels for mixing, with one or more inflow pathways for the addition of components, one or more pathways to allow for testing of contents and one or more pathways for extraction of the product.
- the presence of each such pathway necessarily carries the risk of leakage of a percentage of valuable product, as well as the risk of ingress of one or more contaminating substances, such as dust, bacteria, viruses or chemicals.
- the presence of such contaminants in a therapeutic serum introduced into a patient may produce results ranging from the inefficacy of the serum to the introduction of harmful substances into the patient’s body.
- a flow kit for the continuous purification of a therapeutic protein serum product made of plastic, forming a single, compact, integrated piece comprising a static mixer, a mixing vessel, a plethora of input and outlet lines for the products and the addition of adjusting or processing solutions, a pH probe connection and a sampling connection.
- the flow kit as described herein, wherein the manufacturing process is taken from the group consisting of 3D printing, injection molding, low-pressure molding such as gas-assist molding or structural-foam molding, coinjection, in-mold polymerization, blow molding, shaped thermoforming or another similar method.
- the flow kit as described herein, wherein the plastic is HP 3D High Reusability PA 12 or another commercially available plastic with similar characteristics.
- the flow kit as described herein, wherein the kit is connected by flexible tubing to a separate purification device such as a filter or chromatography column.
- the flow kit as described herein, wherein the kit processes the therapeutic protein serum by optionally mixing with an adjustment solution(s) in the static mixer, delivering the serum to a separate purification device, then optionally mixing the serum with adjustment solution(s) in the mixing vessel.
- a therapeutic protein serum continuous purification system comprising one or more powered pumps, multiple solution containers, multiple flow kits of claim 1, such flow kits interspersed with multiple filters and/or chromatography columns and a collection vessel, each connected by flexible tubing.
- a method of purifying a therapeutic protein serum comprising the steps of:
- Figure l is a line drawing evidencing a perspective view from the static mixer side of a flow kit for the purification of therapeutic protein serum.
- Figure 2 is a line drawing evidencing an alternate view from the mixing vessel side of the flow kit of Fig. 1.
- Figure 3 is a line drawing evidencing a top view of the flow kit of Fig. 1.
- Figure 4 is a line drawing evidencing a perspective view of the flow kit of Fig. 1 with arrows showing the fluid flow path.
- Figure 5 is a flow chart evidencing a therapeutic protein serum purification system comprising multiple flow kits as shown in the preceding figures. DETAILED DESCRIPTION OF THE INVENTION
- the invention is a flow kit to be employed in the continuous purification of therapeutic protein serum.
- a major point of novelty of the invention is the use of a single, integrated device comprising both a static mixer and mixing vessel, along with multiple lines and ports for the introduction of adjusting and processing solutions, as well as for ingress and egress of the product before, during and after processing.
- the integral nature of the kit provides for a compact device that can be seated alone or in a bank of multiple kits, minimizing flow path links and thus utilizing far less lab bench space than with previous non-integral versions.
- the compact design is enabled by vertical orientation of a static mixer and necessary probes, and the probes’ direct attachment to the mixer via 3D printing of necessary ports. This enables the entire flow path to rest on top of a scale and stir plate in the lab.
- Kits may be at least as small as 6.25 cm length, 4 cm width and 7.25 cm height, or as much as 10 times such size.
- the flow kit dimensions are approximately 12.5 cm length x 8 cm width x 15.5 cm height.
- a flow kit of such size can process 50L cell culture (with 5 g/1 titer) per day.
- the mixing vessel should be sized such that, at the flow rates used, the residence time provides sufficient mixing to achieve a homogenous solution. Flow rates are determined by pressure limitations for a given tube diameter. Larger and smaller tubes and vessel sizes within the kit and without it may be used to increase or decrease the flow rate and to fit the space available for setup.
- Ideal vessel volume sizes for the described flow kit may run from 0.2ml to 200L. In preferable range, such kit would accommodate from 250ml to 5L of fluid. In a more preferred range, the kit would accommodate 500ml to 2L.
- kits can instead be laid out on a tabletop or rack in rows without further need for stabilization.
- a system would comprise a power source, one or more powered pumps to move serum through the system, multiple flow kits and one or more filters or chromatography columns attached to each kit, with the last kit in the system flowing into a collection vessel.
- a purification system involving multiple integral kit units would allow for each unit to be discretely removed and replaced with only a few seconds’ disruption to the system’s processing.
- the units themselves operate disposably should any given unit become clogged or otherwise nonfunctional.
- the manufacturing process of the integral device is to be taken from the group comprising, without limitation, 3D printing, injection molding, low-pressure molding such as gas-assist molding or structural-foam molding, coinjection, in-mold polymerization, blow molding, shaped thermoforming or another similar commercially known method.
- the material used for the flow kit must provide rigidity to allow for durability and the attachment of flexible tubing and/or the connection of other devices such as filters or probes, as well as acceptably low in toxicity.
- the flow kit is made of USP Class VI plastic, which has been tested as safe for pharmaceutical processing use with an acceptable toxicity profile, for example, HP 3D High Reusability PA 12. Such plastic also provides excellent chemical resistance which enables chemical sanitization with acid and base solutions. Such material also has thermal properties allowing for sanitization with steam.
- the kit is made of another known plastic exhibiting sufficient rigidity and durability and usable in one of the preferred methods of manufacture.
- Available plastics especially useful in 3D printing include acrylonitrile butadiene styrene (ABS), polyactic acid (PL A), polyvinyl chloride (PVC), polyethylene terephthalate (PET), PET with T-glase (PETT), copolyesters such as PETG, and polystyrene or high-impact polystyrene (HIPS).
- ABS acrylonitrile butadiene styrene
- PVC polyvinyl chloride
- PET polyethylene terephthalate
- PET PET with T-glase
- copolyesters such as PETG
- HIPS high-impact polystyrene
- Carbon fiber would also be a preferred material.
- the material could be a commercially appropriate metal or alloy such as aluminum or stainless steel.
- a powered pump will generate pressure to push untreated serum into the initial flow kit, and additional pumps may be located between kits or between a kit and filter or
- the main components of the integral flow kit are a static mixer and instrument ports on one side and vented mixing vessel on the other, each embodied as a chamber within the kit body accessed by various channels (also referred to as lines) also within the kit body.
- an external input line such line transmits the product directly into the static mixer space.
- a separate input line for adjusting or processing solutions, such as acid, base or buffer also flows directly to the static mixer, wherein such solution(s) is mixed with the newly introduced serum product to achieve the desired pH, conductivity, or buffer concentration.
- Said mixture is then transported through a static mixer, through instrument and sample ports and to a port with a hose barb for transportation out of the kit and towards a separate purification device comprising either a filtration device or a chromatography column.
- the purification technologies i.e. chromatography column or filtration device
- a single flow kit can be used with a single chromatography column or filtration device or multiple columns or filters may be connected in series or parallel within a single flow kit (ex. a depth filter, 0.2um filter to minimize bioburden, anion exchange filter and virus filter can all be connected in series without exceeding pressure limitations).
- the therapeutic protein serum is redirected to the flow kit via flexible tubing connected to a mixing vessel input line, thereby flowing directly into the mixing vessel.
- a separate mixing vessel solution input line designed to be sub-surface, is also located on the outer surface of the kit and can be attached to flexible tubing providing for input of further adjusting or processing solutions such as, but not limited to, acid or base.
- this line can be used to neutralize the pH of the product or adjust the pH, conductivity or concentration of the product to meet the requirements of the subsequent step.
- this line can be used to siphon diafiltration buffer to provide continuous diafiltration in combination with inline concentration membranes.
- the mixing vessel also comprises a vent or filter attachment embodied as another line between the mixing vessel and the outer surface of the kit body, such vent to create a pressure break for a reduction or elimination of pressure within the mixing vessel.
- a vent or filter attachment embodied as another line between the mixing vessel and the outer surface of the kit body, such vent to create a pressure break for a reduction or elimination of pressure within the mixing vessel.
- the static mixer is used to adjust the serum to meet the pH, conductivity and concentration profile required to perform purification on the chromatography or filtration device. Then, the mixing vessel is used to adjust the pH, conductivity or concentration of the product after it leaves the purification device to ensure it is stable or to achieve the desired composition for the subsequent step or final product collection.
- the column provides the required residence time at a low pH to provide viral inactivation.
- Single-pass diafiltration requires no inline adjustment with the static mixer prior to use of the tangential flow filtration (TFF) membrane but requires addition of diafiltration buffer into the mixing vessel to dilute the product to its original (or newly specified) concentration.
- Diafiltration is achieved with multiple (at least three) flow kits in series, each attached to one TFF membrane, to provide consecutive concentration and dilution steps.
- connection components of the flow kit such as connections for pH probes or sampling, are to be embodied as tri-clamp ports.
- Such ports may be fitted with rubber or rubber-like gaskets to effect a leak-proof seal.
- the ends of various input and outlet lines extending outward from the kit body each end in a flared port barb to allow for a tight overlay of flexible tubing for the fluid moving towards or away from the kit.
- Such port barbs may be integral to the kit and overlayed with a layer of rubber or rubber-like plastic to create a tight seal with the flexible tubing, luer locks or similar known fluid transmission features.
- the barbs themselves may be made of such rubber-like material.
- Figure 1 shows a perspective view of a flow kit 100 for the purification of therapeutic protein serum as seen from the from the static mixer 110 side.
- the therapeutic protein serum to be processed by the flow kit 100 is introduced through product input line 112 and flows directly into static mixer
- the pH probe connection 130 is embodied as an open port into which a pH measuring device may be inserted and/or locked, to measure the pH level of the therapeutic protein serum after processing in the static mixer 110.
- the sampling connection 140 is embodied similarly as an open port into which a sampling device (not pictured) may be inserted and/or locked to collect a sample of the therapeutic protein serum after processing in the static mixer for further testing.
- Figure 2 shows a perspective view of the alternate, mixing vessel 120 side of the flow kit 100 of Fig. 1. Processed serum solution from the separate purification device (not pictured) is reintroduced to the kit via flexible tubing attached to the mixing vessel input line 122, and thus directly into the mixing vessel 120.
- a vent 124 which can also be used as a filter attachment in certain embodiments.
- Another point of input is a mixing vessel solution input line 121, preferably located sub-surface to enable siphoning for diafitration, which can be used to introduce further fluid for adjustment or processing of the serum product inside the mixing vessel, after which mixing the processed serum flows into a product output line 123, for delivery to another kit (not pictured) for further processing or to a collection vessel (not pictured).
- An auxiliary connection 150 embodied as a circular port, is also provided between the outside of the kit body and the mixing vessel, such auxiliary connection available for one or more uses, including but not limited to sample collection, pH probe connection, or insertion of a stir bar.
- Figure 3 shows a top view emphasizing the various points of connection on top of the flow kit 100 for the fluids to be put into and extracted from the kit.
- the top of the flow kit comprises a product input line 112 for introduction of serum and a static mixer outlet line 113 for transmission of the serum after processing in the static mixer 110 to a filtration device or chromatography column (not pictured).
- a static mixer input line 111 for the introduction of solutions to treat and purify the serum such as pH adjusting agents
- a mixing vessel input line 121 for the introduction of treatment and purification agents
- a product outlet line 123 for the outflow of treated serum product either to a collection vessel or another flow kit (not pictured).
- the top of the flow kit comprises a mixing vessel input line 122 carrying processed serum from the filtration device or chromatography column (not pictured) into the mixing vessel for further processing, and a mixing vessel filter attachment 124 for the optional attachment of a vent filter or for venting purposes.
- Each component evidenced on top of the flow kit is a port embodied as a barbed tube connection onto which a flexible tube or line may be overlaid.
- Each such component is manufactured through 3d printing, injection molding or a similar process as a part of the larger flow kit 100 and thus is integral to the invention.
- the flared port barb 160 of each component provides a stable, anchoring platform around which a flexible plastic or rubber tube may be arranged to create a seal to prevent leakage or contamination as fluids are introduced into or extracted from the flow kit.
- Figure 4 shows another perspective view of the flow kit 100 embodiment of Fig. 1, also including arrows indicating the flow pattern of fluids (not pictured) moving into and out of the flow kit.
- the therapeutic protein serum product moves in through product input line 112, through static mixer 110 for processing and out through static mixer outlet line 113 to the filtration device or chromatography column, back in through mixing vessel input line 122, through the mixing vessel 120, and finally out through the product outlet line 123 and on to either a final collection vessel or to another flow kit for further processing.
- the dotted arrows indicated pathways for input of adjusting or processing solutions into static mixer 110 through static mixer solution input line 111 and into mixing vessel 120 through mixing vessel solution input line 121.
- Figure 5 shows a flow chart evidencing the flow patterns of serum through a system comprising the flow kits 100 and other devices pictured in Fig. 4.
- the fluid begins in a collection vessel 180, is pumped by a pump 200 to a first flow kit 100, thence to a purification device 190 comprising either a filter or chromatography column, back to the first flow kit, thence to a second flow kit 100, thence to a second purification device, back to the second flow kit, and then to a final collection vessel 180.
- adjusting solutions are added optionally via one or two pumps 200, each pumping solution from a solution container 210.
- Placement of pumps in the system may vary between different iterations, for example residing between the solution container or collection vessel and flow kit, or alternatively on the opposite side of the flow kit from such solution container or collection vessel. Additional steps comprising additional flow kits, purification devices, etc. may be added without limitation. Arrows in the chart evidence flexible tubing attaching the components. Additional components, such as pH probes or sampling devices, may optionally be attached to one or more flow kits and not pictured.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/263,855 US10981950B2 (en) | 2019-01-31 | 2019-01-31 | Therapeutic protein flow kit for a continuous purification system |
PCT/US2020/012387 WO2020159672A1 (en) | 2019-01-31 | 2020-01-06 | Therapeutic protein flow kit for a continuous purification system |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3917559A1 true EP3917559A1 (en) | 2021-12-08 |
EP3917559A4 EP3917559A4 (en) | 2022-11-02 |
EP3917559C0 EP3917559C0 (en) | 2024-03-27 |
EP3917559B1 EP3917559B1 (en) | 2024-03-27 |
Family
ID=71835945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20748801.6A Active EP3917559B1 (en) | 2019-01-31 | 2020-01-06 | Therapeutic protein flow kit for a continuous purification system |
Country Status (3)
Country | Link |
---|---|
US (1) | US10981950B2 (en) |
EP (1) | EP3917559B1 (en) |
WO (1) | WO2020159672A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021107394A1 (en) * | 2021-03-24 | 2022-09-29 | Sartorius Stedim Biotech Gmbh | Device for continuous virus inactivation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693834A (en) | 1986-05-05 | 1987-09-15 | Murex Corporation | Transverse flow diagnostic kit |
EP1355710A4 (en) | 2001-01-05 | 2005-01-26 | Pro Chem Inc | Devices and methods for purification |
WO2005022026A1 (en) * | 2003-08-28 | 2005-03-10 | Mitsubishi Rayon Co., Ltd. | High-performance pressure vessel and carbon fiber for pressure vessel |
US8920645B2 (en) | 2005-12-07 | 2014-12-30 | Tarpon Biosystems Inc. | Disposable chromatography valves and system |
US9109193B2 (en) * | 2007-07-30 | 2015-08-18 | Ge Healthcare Bio-Sciences Corp. | Continuous perfusion bioreactor system |
JP6087293B2 (en) * | 2011-01-06 | 2017-03-01 | メソ スケール テクノロジーズ エルエルシー | Assay cartridge and method of using the same |
JP2014514060A (en) * | 2011-04-01 | 2014-06-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Dialysis treatment (DLT) device |
SG10201701224UA (en) * | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
EP2656892A1 (en) * | 2012-04-23 | 2013-10-30 | Merck Patent GmbH | Chromatography method |
EP2682168A1 (en) * | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
DE102017110482A1 (en) * | 2017-05-15 | 2018-11-15 | Sartorius Stedim Biotech Gmbh | Filtration module or cleaning module for modular filtration system |
-
2019
- 2019-01-31 US US16/263,855 patent/US10981950B2/en active Active
-
2020
- 2020-01-06 EP EP20748801.6A patent/EP3917559B1/en active Active
- 2020-01-06 WO PCT/US2020/012387 patent/WO2020159672A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10981950B2 (en) | 2021-04-20 |
EP3917559A4 (en) | 2022-11-02 |
EP3917559C0 (en) | 2024-03-27 |
WO2020159672A1 (en) | 2020-08-06 |
EP3917559B1 (en) | 2024-03-27 |
US20200247844A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016259745B2 (en) | Method for the continuous elution of a product from chromatography columns | |
RU2676639C2 (en) | Ultrafiltration unit for continuous buffer or media replacement from protein solution | |
US10207225B2 (en) | Single-pass filtration systems and processes | |
Penne et al. | Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice | |
JP6862000B2 (en) | Recirculation loop in CFF / TFF disposable flow path | |
US20070295651A1 (en) | Dialysis bag system | |
EP3917559B1 (en) | Therapeutic protein flow kit for a continuous purification system | |
US11951241B2 (en) | Peritoneal dialysis system and methods | |
EP3431173A1 (en) | Continuous manufacture of guidance molecule drug conjugates | |
JP2020507333A (en) | Degassing in continuous treatment of healthcare products | |
TWI490171B (en) | System and device for purifying and dispensing water, with separation barrier eliminating bacterial contamination | |
JP2024020456A (en) | Integrated and continuous recombinant protein production | |
JP2021506377A (en) | Work unit and its use | |
US11547957B2 (en) | Method of maintaining narrow residence time distributions in continuous flow systems | |
US20240009601A1 (en) | Final Fill Assembly and Method of Integrity Testing | |
TW201840342A (en) | Non-sterile waste removal from a sterile process | |
US20220265909A1 (en) | Indirect drain flush system for dialysis effluent | |
Tarrach et al. | Integration of Large-Scale Chromatography with Nanofiltration for an Ovine Polyclonal Product | |
Runyon | A reliable method for producing highly purified water. | |
CN116963821A (en) | System and method for single pass countercurrent diafiltration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210805 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602020027977 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0038470000 Ipc: B01F0023451000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0038470000 Ipc: B01F0023451000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220929 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01F 25/42 20220101ALI20220923BHEP Ipc: A61K 47/68 20170101ALI20220923BHEP Ipc: A61K 39/395 20060101ALI20220923BHEP Ipc: A61K 38/47 20060101ALI20220923BHEP Ipc: B01D 15/12 20060101ALI20220923BHEP Ipc: B01D 15/08 20060101ALI20220923BHEP Ipc: B01F 23/451 20220101AFI20220923BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20231010 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020027977 Country of ref document: DE |